Aims: To examine the role of the enzyme methionine sulfoxide reductase A-1 (MSRA-1) in amyloid-β peptide (Aβ)-peptide aggregation and toxicity in vivo, using a Caenorhabditis elegans model of the human amyloidogenic disease inclusion body myositis. Results: MSRA-1 specifically reduces oxidized methionines in proteins. Therefore, a deletion of the msra-1 gene was introduced into transgenic C. elegans worms that express the Aβ-peptide in muscle cells to prevent the reduction of oxidized methionines in proteins. In a constitutive transgenic Aβ strain that lacks MSRA-1, the number of amyloid aggregates decreases while the number of oligomeric Aβ species increases. These results correlate with enhanced synaptic dysfunction and mislocalization of the nicotinic acetylcholine receptor ACR-16 at the neuromuscular junction (NMJ). Innovation: This approach aims at modulating the oxidation of Aβ in vivo indirectly by dismantling the methionine sulfoxide repair system. The evidence presented here shows that the absence of MSRA-1 influences Aβ aggregation and aggravates locomotor behavior and NMJ dysfunction. The results suggest that therapies which boost the activity of the Msr system could have a beneficial effect in managing amyloidogenic pathologies. Conclusion: The absence of MSRA-1 modulates Aβ-peptide aggregation and increments its deleterious effects in vivo. Antioxid. Redox Signal. 22, 48–62.
Get full access to this article
View all access options for this article.
References
1.
AldunateR, MinnitiAN, RebolledoD, and InestrosaNC. Synaptic defects associated with s-inclusion body myositis are prevented by copper. Biometals, 25: 815–824, 2012.
2.
AmatoAA and BarohnRJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry, 80: 1186–1193, 2009.
3.
AskanasV and EngelWK. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol, 19: 550–559, 2007.
4.
AskanasV and EngelWK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology, 66: S39–S48, 2006.
5.
AskanasV and EngelWK. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol, 116: 583–595, 2008.
6.
AskanasV and EngelWK. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-beta42 oligomers and phosphorylated tau. Presse Med, 40: e219–e235, 2011.
7.
AskanasV, EngelWK, and NogalskaA. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol, 71: 680–693, 2012.
8.
BuckinghamSD, JonesAK, BrownLA, and SattelleDB. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev, 61: 39–61, 2009.
9.
ButterfieldDA. Amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res, 36: 1307–1313, 2002.
10.
ButterfieldDA and Boyd-KimballD. The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta, 1703: 149–156, 2005.
11.
ButterfieldDA and BushAI. Alzheimer's amyloid beta-peptide (1–42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging, 25: 563–568, 2004.
12.
ButterfieldDA, GalvanV, LangeMB, TangH, SowellRA, SpilmanP, FombonneJ, GorostizaO, ZhangJ, SultanaR, and BredesenDE. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med, 48: 136–144, 2010.
13.
ButterfieldDA and SultanaR. Methionine-35 of abeta(1–42): importance for oxidative stress in Alzheimer disease. J Amino Acids, 2011: 198430, 2011.
14.
ButterfieldDA, SwomleyAM, and SultanaR. Amyloid beta-peptide (1–42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal, 19: 823–835, 2013.
15.
ClementiME, PezzottiM, OrsiniF, SampaoleseB, MezzogoriD, GrassiC, GiardinaB, and MisitiF. Alzheimer's amyloid beta-peptide (1–42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem Biophys Res Commun, 342: 206–213, 2006.
16.
DalakasMC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol, 10: 346–352, 2010.
17.
DostalV, RobertsCM, and LinkCD. Genetic mechanisms of coffee extract protection in a Caenorhabditis elegans model of beta-amyloid peptide toxicity. Genetics, 186: 857–866, 2010.
18.
DrakeJ, LinkCD, and ButterfieldDA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1–42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging, 24: 415–420, 2003.
19.
FayDS, FluetA, JohnsonCJ, and LinkCD. In vivo aggregation of beta-amyloid peptide variants. J Neurochem, 71: 1616–1625, 1998.
20.
GabbitaSP, AksenovMY, LovellMA, and MarkesberyWR. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem, 73: 1660–1666, 1999.
21.
GrassiF, PalmaE, ToniniR, AmiciM, BallivetM, and EusebiF. Amyloid beta(1–42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors. J Physiol, 547: 147–157, 2003.
22.
HanselA, HeinemannSH, and HoshiT. Heterogeneity and function of mammalian MSRs: enzymes for repair, protection and regulation. Biochim Biophys Acta, 1703: 239–247, 2005.
23.
HouL, KangI, MarchantRE, and ZagorskiMG. Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1–42) peptide of Alzheimer's disease. J Biol Chem, 277: 40173–40176, 2002.
24.
HouL, LeeHG, HanF, TedescoJM, PerryG, SmithMA, and ZagorskiMG. Modification of amyloid-beta1-42 fibril structure by methionine-35 oxidation. J Alzheimers Dis, 37: 9–18, 2013.
25.
HouL, ShaoH, ZhangY, LiH, MenonNK, NeuhausEB, BrewerJM, ByeonIJ, RayDG, VitekMP, IwashitaT, MakulaRA, PrzybylaAB, and ZagorskiMG. Solution NMR studies of the A beta(1–40) and A beta(1–42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc, 126: 1992–2005, 2004.
26.
JohanssonAS, BergquistJ, VolbrachtC, PaivioA, LeistM, LannfeltL, and Westlind-DanielssonA. Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation. Neuroreport, 18: 559–563, 2007.
27.
KamathRS, FraserAG, DongY, PoulinG, DurbinR, GottaM, KanapinA, Le BotN, MorenoS, SohrmannM, WelchmanDP, ZipperlenP, and AhringerJ. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature, 421: 231–237, 2003.
28.
KimHY and GladyshevVN. Methionine sulfoxide reductases: selenoprotein forms and roles in antioxidant protein repair in mammals. Biochem J, 407: 321–329, 2007.
29.
LaFerlaFM, GreenKN, and OddoS. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev, 8: 499–509, 2007.
30.
LaFerlaFM and OddoS. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med, 11: 170–176, 2005.
31.
LeeBC, LeeYK, LeeHJ, StadtmanER, LeeKH, and ChungN. Cloning and characterization of antioxidant enzyme methionine sulfoxide-S-reductase from Caenorhabditis elegans. Arch Biochem Biophys, 434: 275–281, 2005.
32.
LinkCD. C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol, 41: 1007–1013, 2006.
33.
LotzBP, EngelAG, NishinoH, StevensJC, and LitchyWJ. Inclusion body myositis. Observations in 40 patients. Brain, 112 (Pt 3): 727–747, 1989.
34.
MaitiP, LomakinA, BenedekGB, and BitanG. Despite its role in assembly, methionine 35 is not necessary for amyloid beta-protein toxicity. J Neurochem, 113: 1252–1262, 2010.
35.
MartinezJ, LisaS, SanchezR, KowalczykW, ZuritaE, TeixidoM, GiraltE, AndreuD, AvilaJ, and GassetM. Selenomethionine incorporation into amyloid sequences regulates fibrillogenesis and toxicity. PloS One, 6: e27999, 2011.
36.
MasliahE, MalloryM, AlfordM, DeTeresaR, HansenLA, McKeelDWJr., and MorrisJC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology, 56: 127–129, 2001.
37.
McCollG, RobertsBR, GunnAP, PerezKA, TewDJ, MastersCL, BarnhamKJ, ChernyRA, and BushAI. The Caenorhabditis elegans A beta 1–42 model of Alzheimer disease predominantly expresses A beta 3–42. J Biol Chem, 284: 22697–22702, 2009.
38.
McFerrinJ, EngelWK, and AskanasV. Impaired innervation of cultured human muscle overexpressing betaAPP experimentally and genetically: relevance to inclusion-body myopathies. Neuroreport, 9: 3201–3205, 1998.
39.
MinnitiAN, CataldoR, TrigoC, VasquezL, MujicaP, LeightonF, InestrosaNC, and AldunateR. Methionine sulfoxide reductase A expression is regulated by the DAF-16/FOXO pathway in Caenorhabditis elegans. Aging cell, 8: 690–705, 2009.
40.
MinnitiAN, RebolledoDL, GrezPM, FadicR, AldunateR, VolitakisI, ChernyRA, OpazoC, MastersC, BushAI, and InestrosaNC. Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification. Mol Neurodegeneration, 4: 2, 2009.
41.
MisitiF, ClementiME, and GiardinaB. Oxidation of methionine 35 reduces toxicity of the amyloid beta-peptide(1–42) in neuroblastoma cells (IMR-32) via enzyme methionine sulfoxide reductase A expression and function. Neurochem Int, 56: 597–602, 2010.
42.
MoskovitzJ, Bar-NoyS, WilliamsWM, RequenaJ, BerlettBS, and StadtmanER. Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc Natl Acad Sci U S A, 98: 12920–12925, 2001.
43.
MoskovitzJ, BerlettBS, PostonJM, and StadtmanER. The yeast peptide-methionine sulfoxide reductase functions as an antioxidant in vivo. Proc Natl Acad Sci U S A, 94: 9585–9589, 1997.
44.
MoskovitzJ, FlescherE, BerlettBS, AzareJ, PostonJM, and StadtmanER. Overexpression of peptide-methionine sulfoxide reductase in Saccharomyces cerevisiae and human T cells provides them with high resistance to oxidative stress. Proc Natl Acad Sci U S A, 95: 14071–14075, 1998.
45.
MoskovitzJ, JenkinsNA, GilbertDJ, CopelandNG, JurskyF, WeissbachH, and BrotN. Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. Proc Natl Acad Sci U S A, 93: 3205–3208, 1996.
46.
MoskovitzJ, MaitiP, LopesDH, OienDB, AttarA, LiuT, MittalS, HayesJ, and BitanG. Induction of methionine-sulfoxide reductases protects neurons from amyloid beta-protein insults in vitro and in vivo. Biochemistry, 50: 10687–10697, 2011.
47.
MoskovitzJ, PostonJM, BerlettBS, NosworthyNJ, SzczepanowskiR, and StadtmanER. Identification and characterization of a putative active site for peptide methionine sulfoxide reductase (MsrA) and its substrate stereospecificity. J Biol Chem, 275: 14167–14172, 2000.
48.
MoskovitzJ, WeissbachH, and BrotN. Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. Proc Natl Acad Sci U S A, 93: 2095–2099, 1996.
49.
MuckeL, MasliahE, YuGQ, MalloryM, RockensteinEM, TatsunoG, HuK, KholodenkoD, Johnson-WoodK, and McConlogueL. High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci, 20: 4050–4058, 2000.
50.
NimmrichV and EbertU. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid. Rev Neurosci, 20: 1–12, 2009.
51.
NogalskaA, D'AgostinoC, EngelWK, and AskanasV. Activation of the gamma-secretase complex and presence of gamma-secretase-activating protein may contribute to Abeta42 production in sporadic inclusion-body myositis muscle fibers. Neurobiol Dis, 48: 141–149, 2012.
52.
NogalskaA, D'AgostinoC, EngelWK, KleinWL, and AskanasV. Novel demonstration of amyloid-beta oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol, 120: 661–666, 2010.
53.
OienDB and MoskovitzJ. Substrates of the methionine sulfoxide reductase system and their physiological relevance. Curr Top Dev Biol, 80: 93–133, 2008.
54.
PetropoulosI, MaryJ, PerichonM, and FriguetB. Rat peptide methionine sulphoxide reductase: cloning of the cDNA, and down-regulation of gene expression and enzyme activity during aging. Biochem J, 355: 819–825, 2001.
55.
PymLJ, BuckinghamSD, TsetlinV, BoydCA, and SattelleDB. The Abeta1-42M35C mutated amyloid peptide Abeta1-42 and the 25–35 fragment fail to mimic the subtype-specificity of actions on recombinant human nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4). Neurosci Lett, 427: 28–33, 2007.
56.
RebolledoDL, AldunateR, KohnR, NeiraI, MinnitiAN, and InestrosaNC. Copper reduces Abeta oligomeric species and ameliorates neuromuscular synaptic defects in a C. elegans model of inclusion body myositis. J Neurosci, 31: 10149–10158, 2011.
57.
RebolledoDL, MinnitiAN, GrezPM, FadicR, KohnR, and InestrosaNC. Inclusion body myositis: a view from the Caenorhabditis elegans muscle. Mol Neurobiol, 38: 178–198, 2008.
58.
RipoliC, PiacentiniR, RiccardiE, LeoneL, Li PumaDD, BitanG, and GrassiC. Effects of different amyloid beta-protein analogues on synaptic function. Neurobiol Aging, 34: 1032–1044, 2013.
59.
SattelleDB and BuckinghamSD. Invertebrate studies and their ongoing contributions to neuroscience. Invert Neurosci, 6: 1–3, 2006.
60.
SchallreuterKU, RubsamK, ChavanB, ZothnerC, GillbroJM, SpencerJD, and WoodJM. Functioning methionine sulfoxide reductases A and B are present in human epidermal melanocytes in the cytosol and in the nucleus. Biochem Biophys Res Commun, 342: 145–152, 2006.
61.
SelkoeDJ. Alzheimer's disease is a synaptic failure. Science (New York, NY. 298: 789–791, 2002.
62.
SelkoeDJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res, 192: 106–113, 2008.
63.
SivanesanS, TanA, and RajadasJ. Pathogenesis of Abeta oligomers in synaptic failure. Curr Alzheimer Res, 10: 316–323, 2013.
64.
StiernagleT. Maintenance of C. elegans. WormBook e: The C. elegans Research Community, WormBook, 2006. DOI: DOI:10.1895/wormbook.1.101.1, http://www.wormbook.org
65.
SultanaR, RobinsonRA, LangeMB, FioriniA, GalvanV, FombonneJ, BakerA, GorostizaO, ZhangJ, CaiJ, PierceWM, BredesenDE, and ButterfieldDA. Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alzheimer disease pathogenesis?. Antioxid Redox Signal, 17: 1507–1514, 2012.
66.
ToledoEM and InestrosaNC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry, 15: 272–285, 228, 2009.
67.
TsengBP, KitazawaM, and LaFerlaFM. Amyloid beta-peptide: the inside story. Curr Alzheimer Res, 1: 231–239, 2004.
VattemiG, NogalskaA, King EngelW, D'AgostinoC, CheclerF, and AskanasV. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol, 117: 569–574, 2009.
70.
WangHY, LeeDH, D'AndreaMR, PetersonPA, ShankRP, and ReitzAB. beta-Amyloid(1–42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem, 275: 5626–5632, 2000.
71.
WilcoxKC, LacorPN, PittJ, and KleinWL. Abeta oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol, 31: 939–948, 2011.
72.
WuY, WuZ, ButkoP, ChristenY, LambertMP, KleinWL, LinkCD, and LuoY. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci, 26: 13102–13113, 2006.
73.
YatinSM, VaradarajanS, LinkCD, and ButterfieldDA. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1–42). Neurobiol Aging, 20: 325–330; discussion 339–342, 1999.
74.
YeCP, SelkoeDJ, and HartleyDM. Protofibrils of amyloid beta-protein inhibit specific K+ currents in neocortical cultures. Neurobiol Dis, 13: 177–190, 2003.
75.
ZhangXH and WeissbachH. Origin and evolution of the protein-repairing enzymes methionine sulphoxide reductases. Biol Rev Camb Philos Soc, 83: 249–257, 2008.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
